Stock AMGN AMGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Amgen Inc. Stock

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-02 pm EDT 		After market 07:55:37 pm
278.4 USD +0.37% Intraday chart for Amgen Inc. 318.3 +14.34%
May. 02 Amgen Expects Full-Year 2024 Share Repurchases Not to Exceed $500 Million MT
May. 02 Amgen Q1 Non-GAAP Earnings Decline, Revenue Increases; Adjusts Full-Year Guidance; Shares Advance After Hours MT

Financials (USD)

Sales 2024 * 32.96B Sales 2025 * 34.15B Capitalization 149B
Net income 2024 * 6.12B Net income 2025 * 7.58B EV / Sales 2024 * 5.94 x
Net Debt 2024 * 46.35B Net Debt 2025 * 40.16B EV / Sales 2025 * 5.55 x
P/E ratio 2024 *
24.3 x
P/E ratio 2025 *
18.8 x
Employees 26,700
Yield 2024 *
3.33%
Yield 2025 *
3.6%
Free-Float 99.75%
More Fundamentals * Assessed data

Chart Amgen Inc.

Dynamic Chart

Latest news about Amgen Inc.

Amgen Expects Full-Year 2024 Share Repurchases Not to Exceed $500 Million MT
Amgen Q1 Non-GAAP Earnings Decline, Revenue Increases; Adjusts Full-Year Guidance; Shares Advance After Hours MT
Amgen Posts Higher 1Q Revenue, Swings to Loss DJ
Transcript : Amgen Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (AMGN) AMGEN Reports Q1 EPS $3.96, vs. Street Est of $3.89 MT
Earnings Flash (AMGN) AMGEN Reports Q1 Revenue $7.45B, vs. Street Est of $7.453B MT
Amgen Guides For Full Year 2024 EPS of $19-$20.20 on Revenue of $32.5-$33.8 Billion, vs CIQ Analyst Consensus of $19.53/Share on Revenue of $32.9 Billion MT
Amgen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Amgen first-quarter profit dips 1%, revenue rises 22% RE
Equity Markets Higher Ahead of Apple Earnings MT
S&P 500, Nasdaq Rise Intraday Amid Moderna Rally as Traders Await Apple Results MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple... Our Logo
Stock Futures Gain Pre-Bell as Fed Leaves Key Rate Unchanged; Asia, Europe Churn MT
European Midday Briefing : Stocks Steady as Powell Suggests Rate Hike Unlikely DJ
Chimeric Therapeutics Appoints COO; Shares Rise 4% MT
More news

Latest transcript on Amgen Inc.

Logo Amgen Inc.
Amgen Inc., Q1 2024 Earnings Call, May 02, 2024
More transcripts

Analyst Recommendations on Amgen Inc.

UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating MT
TD Cowen Cuts Price Target on Amgen to $360 From $370, Buy Rating Kept MT
Goldman Sachs Adjusts Amgen Price Target to $359 From $361, Maintains Buy Rating MT
BMO Lowers Price Target on Amgen to $336 From $343 MT
Morgan Stanley Cuts Price Target on Amgen to $271 From $278, Keeps Equalweight Rating MT
More recommendations

Press releases Amgen Inc.

Amgen: Q1 Earnings Snapshot AQ
Amgen : Getting Older and Still Standing Tall PU
Amgen : Update on Patent Litigation Related to Sandoz Denosumab Biosimilar Products PU
AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS PR
AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY PR
More press releases

News in other languages on Amgen Inc.

Amgen steigert Umsatz kräftig - Abnehmpille sorgt beim Aktienkurs für Höhenflüge
MIDDAY BRIEFING - Unternehmen und Märkte
TAGESVORSCHAU/Donnerstag, 2. Mai
MORNING BRIEFING - USA/Asien
MORNING BRIEFING - Deutschland/Europa
More news

Quotes and Performance

1 day+14.34%
1 week+3.34%
Current month+1.62%
1 month+0.79%
3 months-13.86%
6 months+4.43%
Current year-3.34%
More quotes

Highs and lows

1 week
268.99
Extreme 268.99
279.84
1 month
260.68
Extreme 260.68
279.84
Current year
260.68
Extreme 260.68
329.72
1 year
211.71
Extreme 211.71
329.72
3 years
198.64
Extreme 198.64
329.72
5 years
166.30
Extreme 166.3
329.72
10 years
109.41
Extreme 109.41
329.72
More quotes

Managers and Directors - Amgen Inc.

Managers TitleAgeSince
Robert Bradway CEO
 Chief Executive Officer 61 06-05-31
Peter Griffith DFI
 Director of Finance/CFO 65 19-10-22
James Bradner CTO
 Chief Tech/Sci/R&D Officer 52 Dec. 17
Members of the board TitleAgeSince
Charles Holley BRD
 Director/Board Member 67 17-02-02
Ellen Kullman BRD
 Director/Board Member 68 16-10-13
Robert Williams BRD
 Director/Board Member 75 14-10-16
More insiders

ETFs positioned on Amgen Inc.

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
7.84% 0 M€ 0.00% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
7.63% 0 M€ 0.00% -
NOMURA NEXT FUNDS DOW JONES INDUSTRIAL AVERAGE ETF - JPY ETF Nomura NEXT FUNDS Dow Jones Industrial Average ETF - JPY
5.08% 120 M€ +11.38% -
More ETFs positioned on Amgen Inc.

Quotes

Date Price Change Volume
24-05-02 278.4 +0.37% 3,177,473
24-05-01 277.4 +1.25% 2,323,935
24-04-30 273.9 -0.88% 2,477,347
24-04-29 276.4 +2.37% 2,678,969
24-04-26 270 +0.22% 2,436,959

Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT

More quotes

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-20 - American Thoracic Society Conference
Related indices
Dow Jones Industrial , S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Amgen Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
278.4 USD
Average target price
302.9 USD
Spread / Average Target
+8.80%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
AMGEN INC. Stock Amgen Inc.
-3.34% 149B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 699B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 326B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
NOVARTIS AG Stock Novartis AG
+4.71% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 154B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AMGN Stock